ridiculous sell off
aj5rose That is a lie Went To SEC Forms- Insiders Have Only Sold 15,000 In The Last 2 Years
Do the DD Amazing Drug
J&J buys into Achillion's hep C pipeline for up to $1.1B
May 20, 2015 | By Damian Garde
Johnson & Johnson ($JNJ), fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' ($ACHN) pipeline of antiviral treatments.
Under the deal, J&J is making a $225 million investment in its partner and promising up to $905 million in milestone payments in order to get its hands on a group of in-development hep C treatments. The plan is to develop Achillion's drugs in combination with one another and, ideally, come up with a regimen thcan cure the infection in as few as four weeks. Leading the pipeline is ACH-3102, Achillion's Phase II NS5A inhibitor, followed by the complementary ACH-3422 and sovaprevir.
finally a co. where insiders aren't selling
Sentiment: Strong Buy
If you trade biotechs you know this is common. I'm in guys
Sentiment: Strong Buy
Celladon Shares May Have Upside to $70
The developer of gene therapy for heart failure to announce pivotal trial results.
We are initiating coverage of Celladon with a Buy rating and target of $70.
The total annual cost of treating heart failure today is $39 billion in the U.S. alone. By virtue of investment in Celladon, a number of pharmaceutical companies have a front row seat to evaluate the significance of CUPID 2. We anticipate a licensing or a merger and acquisition (M&A) transaction, if results are promising for future success
DD From Last Data:
CUPID data show that heart failure, which is a progressive disease, became stabilized in MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function significantly improved or remained the same while these parameters deteriorated substantiallywith ptientstreated with placebo and concurrent optimal drug and device therapy.The safety profile from thisstudy was very favorable, with no significant side-effects from MYDICAR® therapy L